The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Many women have heavy periods and this can be associated with low blood, tiredness and inability to carry out normal activities. Approximately 10-30% of these women will have an underlying bleeding disorder. There is a drug called tranexamic acid which is commonly used and is effective in reducing menstrual flow. However, up to 1/3 of women have side effects and they are more common at higher doses. In the medical literature, there are different dosing schedules and there is one commonly recommended in Canada. Women with underlying bleeding disorders may require higher doses of this medication compared to those who do not. In this study, the investigators want to find the lowest effective dose of tranexamic acid for girls and women with heavy periods who have bleeding disorders and the investigators think this will be lower then the usual recommended dose. If the investigators' results support this, it may contribute to changing how the investigators presently prescribe this medication and may provide a better option for women with heavy periods in particular those with bleeding disorders. The investigators have just started a Women with Bleeding Disorders Clinic and hope that this project will lead to better care for the patients and more research in the future.
| Condition | Intervention | Phase |
|---|---|---|
|
Menorrhagia |
Drug: tranexamic acid |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Assessment of the Minimal Effective and Tolerated Dose of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders |
- Minimal effective dose of tranexamic acid [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
- Quality of Life Assessment [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 149 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tranexamic acid, Menorrhagia, Bleeding
Tranexamic acid with titrated doses. All women with menorrhagia will take .
|
Drug: tranexamic acid
After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
Other Name: Cyklokapron
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 15 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:Clinical diagnosis of Menorrhagia
- Must be able to swallow tablets
Exclusion Criteria:
- Endometrial abnormality
- Pelvic infection
- Pregnancy
- Breast Feeding
- Requirement for birth control
- Known intolerance/lack of effect of tranexamic acid
Contacts and Locations
More Information
No publications provided
| Responsible Party: | K. Sue Robinson, QE II HSC |
| ClinicalTrials.gov Identifier: | NCT00904709 History of Changes |
| Other Study ID Numbers: | CDHA-RS/2009-341 |
| Study First Received: | May 15, 2009 |
| Last Updated: | May 19, 2009 |
| Health Authority: | Canada: Health Canada |
Additional relevant MeSH terms:
|
Blood Coagulation Disorders Hemostatic Disorders Hemorrhagic Disorders Hemorrhage Menorrhagia Hematologic Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes Uterine Hemorrhage Uterine Diseases |
Genital Diseases, Female Menstruation Disturbances Tranexamic Acid Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Hemostatics Coagulants Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013